Ixico Share News (IXI)

Giulio Cerroni appointed CEO of IXICO

(ShareCast News) - Brain health company IXICO announced on Tuesday that Giulio Cerroni will be appointed to the board as chief executive officer, with effect from 6 February. The AIM-traded firm said Derek Hill, the co-founder and current CEO, will remain on the board and continue to serve as an exe

Ixico joins European syndicate to collect data on Alzheimer's

(ShareCast News) - Brain health company Ixico is to receive €100,000 to provide digital technologies for collection and analysis of data , which further expands its work on wearable bio-sensors as part of a pan-European partnership. The AIM-listed company is to participate in a new collaborative EU

Ixico's income falls slightly but has a number of contracts in the pipeline

(ShareCast News) - AIM-listed Ixico's income for the year fell, but the brain health company has a number of contracts with pharmaceuticals in the pipeline and a "strong" balance sheet. In trading update for the year ended 30 September, the company reported revenues of £3.1m and other income of £700

Ixico to receive €1m from EU Alzheimer's project

(ShareCast News) - AIM-listed pharmaceutical Ixico is to receive €1m as a partner in an EU public-private consortium, which has the potential for long-term revenue through the development of diagnostic and disease management technologies for Alzheimer's. Ixico is to work on the Amyloid Imaging to Pr

IXICO study joins Dementias Platform

(ShareCast News) - Brain health company IXICO announced on Thursday that its Cygnus study has joined the high-profile Dementias Platform UK (DPUK). The AIM-traded firm described Cygnus as a real-world digital data collection study from people with cognitive impairment and dementia. It said the four

Ixico wins four new contracts worth over £3m

(ShareCast News) - Brain health company Ixico was recently awarded four new contracts with "leading" pharmaceutical groups and a specialist biotechnology firm totalling over £3m in value. The contracts involve global clinical trials of novel drugs for Alzheimer's disease spanning three major phases

Ixico full-year income in line with expectations

(ShareCast News) - Brain health company Ixico reported revenues for the year of £3.1m and other income at £1m, in line with market expectations and giving a total combined income of £4.1m. This was down from £4.3m for the 16-month period to 30 September 2014. In a pre-close trading update ahead of

Ixico secures two clinical trial contracts alongside partner VirtualScopics

Ixico has won two contracts to deploy its products in unnamed pharmaceutical companies' clinical trials, alongside its partner VirtualScopics. Both studies will employ Ixico's TrialTracker digital platform to collect and image data, one pertaining to metastatic solid tumours and the other to rare ne

IXICO Appoints CFO For October 1 Start

DIRECTOR DEALINGS: IXICO Divisional Vice-President Buys Shares

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

IXICO Joins Medical Research Council Collaboration For Dementia Drive

LONDON (Alliance News) - IXICO PLC said Thursday it will take part in a GBP16 million collaboration launched by publicly funded government agency the Medical Research Council to speed up research into dementia. The MRC has launched the UK Dementias Research Platform with the aim of seeking

Ixico partners with the Medical Research Council to launch UK Dementias Research Platform

Biotechnology group Ixico has partnered with the Medical Research Council (MRC) to launch the UK Dementias Research Platform (UKDP), a £16m public-private partnership. The group, which set up the partnership to speed up research into dementias, will act as the MRC's imaging partner on the project a

IXICO To Meet Full-Year Expectations As Interim Hit By Listing Costs

LONDON (Alliance News) - IXICO PLC expressed confidence Friday in meeting market expectations for the full year, as it swung into a loss in the half year to end-March, hit by costs relating to its AIM listing and a decline in revenues. The company was formed via the reverse takeover of Phyt